195 related articles for article (PubMed ID: 38323738)
41. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression.
Tolar M; Hey J; Power A; Abushakra S
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34198582
[TBL] [Abstract][Full Text] [Related]
42. Optimal anti-amyloid-beta therapy for Alzheimer's disease via a personalized mathematical model.
Hao W; Lenhart S; Petrella JR
PLoS Comput Biol; 2022 Sep; 18(9):e1010481. PubMed ID: 36054214
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
Wessels AM; Tariot PN; Zimmer JA; Selzler KJ; Bragg SM; Andersen SW; Landry J; Krull JH; Downing AM; Willis BA; Shcherbinin S; Mullen J; Barker P; Schumi J; Shering C; Matthews BR; Stern RA; Vellas B; Cohen S; MacSweeney E; Boada M; Sims JR
JAMA Neurol; 2020 Feb; 77(2):199-209. PubMed ID: 31764959
[TBL] [Abstract][Full Text] [Related]
44. Development of molecular tools for diagnosis of Alzheimer's disease that are based on detection of amyloidogenic proteins.
Kulichikhin KY; Fedotov SA; Rubel MS; Zalutskaya NM; Zobnina AE; Malikova OA; Neznanov NG; Chernoff YO; Rubel AA
Prion; 2021 Dec; 15(1):56-69. PubMed ID: 33910450
[TBL] [Abstract][Full Text] [Related]
45. Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies.
Imbimbo BP; Ippati S; Watling M; Imbimbo C
Pharmacol Res; 2023 Jan; 187():106631. PubMed ID: 36586644
[TBL] [Abstract][Full Text] [Related]
46. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
[TBL] [Abstract][Full Text] [Related]
47. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
[TBL] [Abstract][Full Text] [Related]
48. Passive Alzheimer's immunotherapy: A promising or uncertain option?
Høilund-Carlsen PF; Revheim ME; Costa T; Alavi A; Kepp KP; Sensi SL; Perry G; Robakis NK; Barrio JR; Vissel B
Ageing Res Rev; 2023 Sep; 90():101996. PubMed ID: 37414156
[TBL] [Abstract][Full Text] [Related]
49. Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis.
Fedele E
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833948
[TBL] [Abstract][Full Text] [Related]
50. Lecanemab in Early Alzheimer's Disease.
van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
[TBL] [Abstract][Full Text] [Related]
51. Lecanemab: Appropriate Use Recommendations.
Cummings J; Apostolova L; Rabinovici GD; Atri A; Aisen P; Greenberg S; Hendrix S; Selkoe D; Weiner M; Petersen RC; Salloway S
J Prev Alzheimers Dis; 2023; 10(3):362-377. PubMed ID: 37357276
[TBL] [Abstract][Full Text] [Related]
52. Donanemab (LY3002813) dose-escalation study in Alzheimer's disease.
Lowe SL; Willis BA; Hawdon A; Natanegara F; Chua L; Foster J; Shcherbinin S; Ardayfio P; Sims JR
Alzheimers Dement (N Y); 2021; 7(1):e12112. PubMed ID: 33614890
[TBL] [Abstract][Full Text] [Related]
53. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
Chowdhury S; Chowdhury NS
Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
[TBL] [Abstract][Full Text] [Related]
54. Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model).
Mazer NA; Hofmann C; Lott D; Gieschke R; Klein G; Boess F; Grimm HP; Kerchner GA; Baudler-Klein M; Smith J; Doody RS;
Alzheimers Dement; 2023 Jun; 19(6):2287-2297. PubMed ID: 36454709
[TBL] [Abstract][Full Text] [Related]
55. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
[TBL] [Abstract][Full Text] [Related]
56. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.
Cummings J; Aisen P; Lemere C; Atri A; Sabbagh M; Salloway S
Alzheimers Res Ther; 2021 May; 13(1):98. PubMed ID: 33971962
[No Abstract] [Full Text] [Related]
57. Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42.
Espay AJ; Herrup K; Imbimbo BP; Kepp KP; Daly T
J Alzheimers Dis; 2024; 99(3):877-881. PubMed ID: 38701151
[TBL] [Abstract][Full Text] [Related]
58. Lecanemab: More Questions Than Answers!
Kaur U; Reddy J; Tiwari A; Chakrabarti S; Chakrabarti SS
Clin Drug Investig; 2024 Jan; 44(1):1-10. PubMed ID: 38095822
[TBL] [Abstract][Full Text] [Related]
59. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
[TBL] [Abstract][Full Text] [Related]
60. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.
Avgerinos KI; Ferrucci L; Kapogiannis D
Ageing Res Rev; 2021 Jul; 68():101339. PubMed ID: 33831607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
